This M.E. research round-up covers the following studies: Potential blood test, Brain function worsens after exercise, Trial of an arthritis drug, Recovery experiences. Read the research round-up
Scientific overview of the drug research updates given at the International Association for CFS/ME 2016 conference, written by Cort Johnson.The drugs mentioned are rituximab, cyclophosphamide, desmopressin, low-dose naltrexone, rintatolimod (Ampligen), and some supplements. Heard through @firestormmer. Read Treating ME/CFS: The IACFS/ME Conference Overviews – Part V
2016 was a bumper year for M.E. research, so what needs to happen next to ensure this progress is built upon to improve the lives of the 17 million people with M.E. worldwide?
Today the UK government responded to a petition calling for more investment into M.E./CFS research. I’ve included a summary of the response, a run down of the current projects by the MRC to encourage more research, and links to research news.
I’ve started using Paper.li to automatically publish a weekly paper on Friday evenings made up of the news and research articles I’ve tweeted during the previous week.
Read More »
Only a few days ago, I wrote a blog post, Calls for NICE to change how it assesses treatments about an opinion piece in the Pharmaceutical Journal written by the CEO of the Association of the British Pharmaceutical Industry (ABPI), calling for NICE to speed up the way it assesses cancer drugs, along with medicines for rare diseases.Read More »
There are now 2 opportunities for the UK general public to have our say about treatment in the NHS: the Accelerated Access Review and NHS Citizen Gather. These aren’t exclusive to M.E. but I think they’re opportunities we should take.Read More »
The Association of the British Pharmaceutical Industry (ABPI) is calling for NICE to reform the way it assesses treatments for its guidelines[1], echoing the views I’ve read on social media from health professionals, academics and frustrated patients with long-term conditions such as M.E., fibromyalgia and vitamin B12 deficiency, amongst many others.Read More »
There are two routes from discovery to licensing, depending on whether the drug is a completely new one (de novo pathway) or whether it is an existing drug discovered to be an effective treatment of a different symptom or condition (repositioning pathway).
Read More »
A Prescription for M.E. 